In the context of suppressing primary tumor growth by targeting the tumor vasculature, concurrent Ang1 inhibition was thought to augment the activity of Ang2-specific inhibition (Falcon et al, 2009; Coxon et al, 2010), but metastatic disease was not modeled in these preclinical studies. This evidence concerns the gene ANGPT1 and metastatic neoplasm.